PSMA-PET Tumor Volume Stratifies Nonmetastatic Castration-resistant Prostate Cancer
European Urology Focus · 2026-10 · 12 (5) · 939-947
DOI: 10.1016/j.euf.2026.06.006 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift European Urology Focus, 2026-10. Verfasst von Caner Civan und 23 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, DKTK and NCT University Hospital Essen, Essen, Germany; Department of Nuclear Medicine, Faculty of Medicine and Unive…. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant, Positron-Emission Tomography, Antigens, Surface, Glutamate Carboxypeptidase II. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: AstraZeneca PLC, German Research Foundation, Agencja Badań Medycznych.
Abstract (Originalsprache)
BACKGROUND AND OBJECTIVE: Prostate-specific membrane-antigen positron emission tomography (PSMA-PET) detects distant metastases in more than half of patients with increasing prostate-specific antigen despite castrate levels of testosterone and high-risk nonmetastatic disease on conventional imaging. Here, we aim to evaluate prognostic implications of PSMA-PET staging in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC). METHODS: Overall, 514 patients who underwent PSMA-PET for nmCRPC at investigator sites across the world between 2013 and 2022, were retrospectively evaluated in a large, international multi-center PROMISE-PET Registry study. PROMISE metrics and PSMA-PET reports were retrospectively analyzed in accordance with PROMISE V2 criteria. Total tumor volume, PSMA expression score, and molecular imaging metastatic disease (miM1) were analyzed to prognosticate overall survival (OS). RESULTS: Median follow-up was 4.4 yr (interquartile range 2.9-6.7). Overall, 294 patients (57%) were deceased at last follow-up. PSMA-PET detected metastatic disease in 340 patients (66%), and visceral metastases in 28 patients (5.4%). The optimal cutoff point for tumor volume was identified as 7.8 ml, which significantly stratified the cohort into low- versus high-volume groups. Patients with high-volume disease had worse OS than those with low-volume disease (hazard ratio [HR], 2.47; 95% confidence interval [CI], 2.22-2.71; p < 0.001). Patients with any distant metastases (miM1) on PSMA-PET had significantly shorter OS compared to those without detectable metastatic disease (HR, 1.74; 95% CI, 1.49-2.00; p < 0.001). CONCLUSION: Higher tumor volume on PSMA-PET and presence of distant metastases were strongly associated with OS in patients with nmCRPC. PSMA-PET stage and tumor volume should be included in future nmCRPC risk stratification.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nuclear Medicine, DKTK and NCT University Hospital Essen, Essen, Germany; Department of Nuclear Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany. Elect…
- Department of Nuclear Medicine, DKTK and NCT University Hospital Essen, Essen, Germany; Department of Nuclear Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany; Depar…
- Department of Urology, DKTK and NCT University Hospital Essen, Essen, Germany.
- Department of Nuclear Medicine, DKTK and NCT University Hospital Essen, Essen, Germany.
- Department of Nuclear Medicine, University Hospital Carl Gustav Carus, Technical University Dresden, Dresden, Germany.
- Department of Radiation Oncology, University Hospital Carl Gustav Carus, Technical University Dresden, Dresden, Germany.
Förderung
- AstraZeneca PLC
- German Research Foundation
- Agencja Badań Medycznych
- Innovative Health Initiative
- Novartis AG
- Prostate Cancer Foundation
- Narodowa Agencja Wymiany Akademickiej
Zitieren
APA
Civan, C., Karpinski, M. J., Darr, C., Selvamoorthy, T., Rennau, L. M., Hoberück, S., Miederer, M., Hölscher, T., Bögemann, M., Schäfers, M., Rauscher, I., Güven, O., Calais, J., Kimura, K., Ufton, D., Miszczyk, M., Hofman, M. S., Hope, T. A., Kesch, C., …, & Rahbar, K. (2026). PSMA-PET Tumor Volume Stratifies Nonmetastatic Castration-resistant Prostate Cancer. European Urology Focus, 12(5), 939-947. https://doi.org/10.1016/j.euf.2026.06.006
Vancouver
Civan C, Karpinski MJ, Darr C, Selvamoorthy T, Rennau LM, Hoberück S, et al. PSMA-PET Tumor Volume Stratifies Nonmetastatic Castration-resistant Prostate Cancer. European Urology Focus. 2026;12(5):939-947. doi:10.1016/j.euf.2026.06.006
BibTeX
@article{Civan2026,
author = {Civan, Caner and Karpinski, Madeleine J and Darr, Christopher and Selvamoorthy, Thanusiah and Rennau, Lisa Marie and Hoberück, Sebastian and Miederer, Matthias and Hölscher, Tobias and Bögemann, Martin and Schäfers, Michael and Rauscher, Isabel and Güven, Osman and Calais, Jeremie and Kimura, Koichiro and Ufton, Dominic and Miszczyk, Marcin and Hofman, Michael S and Hope, Thomas A and Kesch, Claudia and Herrmann, Ken and Hadaschik, Boris and Eiber, Matthias and Fendler, Wolfgang P and Rahbar, Kambiz},
title = {PSMA-PET Tumor Volume Stratifies Nonmetastatic Castration-resistant Prostate Cancer},
journal = {European Urology Focus},
year = {2026},
volume = {12},
number = {5},
pages = {939--947},
doi = {10.1016/j.euf.2026.06.006}
}
EUVIMED